Studies on Hemotoxicity of Cyclophosphamide, Doxorubicin and Cis-Diamminodichloroplatinum Combined with Sodium-2-Mercaptoethane Sulfonate

Lerza, Roberto; Bogliolo, G; Saviane, A; Pannacciulli, I

doi:10.1177/030089168807400316

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The muscles of the femur of the rats sacrificed under ketamine/xylazine anesthesia were resected [28]. Next, the femur was excised by cutting at both ends (Fig 2 .1).…”

Section: Isolation and Counting Of Bone Marrow Nucleated Cellsmentioning

confidence: 99%

Selenyum ve Bor'un Siklofosfamid kaynaklı kemik iliği ve kan toksisitesine karşı koruyucu etkileri: Bir in vivo çalışma

et al. 2022

View full text Add to dashboard Cite

Bor (B) ve Selenyum (Se), antioksidan, anti-apoptotik, anti-lipid peroksidatif ve bağışıklık güçlendirici özellikleri sayesinde insan vücudu için gerekli eser elementlerdir. Bu çalışma, Se ve B'nin Siklofosfamid (SFD) ile indüklenen kemik iliğinde miyeloid koruyucu potansiyellerini ve bu anti-kanser ilacın miyelotoksik özelliğinin kullanımını sınırladığını göz önünde bulundurarak deneysel sıçanlarda hematolojik toksisiteyi karşılaştırmayı amaçlamaktadır. SFD'nin kemik iliği ve kan hücreleri üzerindeki toksik etkilerini önlemede selenyumun bordan daha iyi bir koruyucu etkiye sahip olduğunu varsaydık. Bu eser elementlerin en sık kullanılan optimal dozları olan 1.5 mg/kg Se ve 20 mg/kg B hayvanlara deney boyunca intraperitoneal olarak verildi. Sadece 4. günde 200 mg/kg SFD uygulandı. Hayvanlar sakrifiye edilerek hematolojik değerlendirmeler için kan ve kemik iliği örnekleri alındı. SFD uygulaması, lökosit (WBC), trombosit (PLT), eritrositler (RBC) ve kemik iliği çekirdekli hücre sayılarını önemli ölçüde azalttı. Öte yandan, SFD ile birlikte Se ve B verilen gruplarda, sadece SFD verilenlere göre önemli miktarlarda arttı. Ancak Se'nin, istatistiksel anlamlılık elde edememesine rağmen, SFD'nin neden olduğu kemik iliği ve hematolojik toksisiteyi önlemede B'den daha koruyucu olduğu kanıtlanmıştır. Bu nedenle, bu deneyde kullanılan dozların, kemik iliğinde SFD'nin neden olduğu hasara ve SFD'e bağlı hematolojik toksisiteye karşı korumada başarılı olduğu sonucuna varıldı.

show abstract

“…The muscles of the femur of the rats sacrificed under ketamine/xylazine anesthesia were resected [28]. Next, the femur was excised by cutting at both ends (Fig 2 .1).…”

Section: Isolation and Counting Of Bone Marrow Nucleated Cellsmentioning

confidence: 99%

Selenyum ve Bor'un Siklofosfamid kaynaklı kemik iliği ve kan toksisitesine karşı koruyucu etkileri: Bir in vivo çalışma

et al. 2022

View full text Add to dashboard Cite

show abstract

WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

Treskes

Vijgh

1993

Cancer Chemother. Pharmacol.

102

View full text Add to dashboard Cite

Cisplatin is an active cytostatic that became successful in the treatment of several types of solid tumours after its nephrotoxic potential was controlled by hydration and diuresis. Thiol compounds were tested to reduce further cisplatin-induced nephrotoxicity. Thiosulphate is rapidly excreted by the kidneys and protects against cisplatin-induced nephrotoxicity by inactivating reactive platinum species in the kidney. Due to inactivation of cisplatin in the circulation, thiosulphate also interferes with its antitumour activity. Therefore, it is mainly used in two-route schedules, whereby cisplatin is delivered locally to the tumour (i.p. or i.a.) while systemic (i.v.) thiosulphate protects the kidneys. Diethyldithiocarbamate was shown to protect against cisplatin-induced nephrotoxicity in several animal models by reversing cellular damage. However, in the clinic it has been less successful, partly due to its central nervous system toxicity. The endogenous thiol compounds glutathione and metallothionein have been shown to reduce cisplatin-induced toxicity both in animal models and in clinical trials. However, the results are rather preliminary and a reduction in therapeutic efficacy may be expected, for both glutathione and metallothionein have been reported to be involved in platinum resistance. The thioether methionine has been shown to reduce cisplatin-induced nephrotoxicity in animal models but it has not yet been tested in the clinic. Cisplatin-induced acute emesis can be sufficiently controlled with a new class of 5-hydroxytryptamine-3 (5HT3)-receptor blockers, but delayed emesis remains a problem. High-dose cisplatin regimens with protection of the kidneys induces ototoxicity, peripheral neuropathy and myelotoxicity, which become dose-limiting. Neurotoxicity was partly reversed by the neurogenerative agent ORG2766, but this agent does not reduce other cisplatin-induced toxicities. Therefore, an agent capable of protecting multiple non-tumour tissues is needed. Carboplatin is a second-generation analogue of cisplatin with less nephro-, neuro- and ototoxicity. Carboplatin is at least as active as cisplatin at its maximum tolerated dose, which is defined by its myelotoxicity. Protection from carboplatin-induced myelotoxicity may be controlled by autologous bone marrow transplantation and/or hematopoietic growth factor infusions. High-dose carboplatin schedules may cause nephrotoxicity, neurotoxicity and ototoxicity. Again, the protection of multiple non-tumour tissues is needed. WR2721 appears to be such a modulating agent capable of protecting multiple non-tumour tissues. It was shown to be preferentially metabolized and taken up as the thiol metabolite WR1065 by non-tumour tissues as compared with (hypoxic) solid tumours. It was shown to protect mice from cisplatin-induced nephrotoxicity and from cisplatin- and carboplatin-induced myelotoxicity without interfering with the antitumour activity.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats

Yeh

Kim

Peresie

2008

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Studies on Hemotoxicity of Cyclophosphamide, Doxorubicin and Cis-Diamminodichloroplatinum Combined with Sodium-2-Mercaptoethane Sulfonate

Cited by 3 publications

References 11 publications

Selenyum ve Bor'un Siklofosfamid kaynaklı kemik iliği ve kan toksisitesine karşı koruyucu etkileri: Bir in vivo çalışma

Selenyum ve Bor'un Siklofosfamid kaynaklı kemik iliği ve kan toksisitesine karşı koruyucu etkileri: Bir in vivo çalışma

WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats

Contact Info

Product

Resources

About